Symbols

BLRX

BioLineRx·NASDAQ

--(--)

Signals Analysis

Bullish signal 2

Bearish signal 1

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About BLRX

Biolinerx Ltd.

A late clinical-stage biopharmaceutical company focused on oncology

Industry

Biological Technology

Established Date

Listing Date

07/25/2011

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.biolinerx.com

Security Type

Depository Receipts (Ordinary Shares)

Office address

2 HaMa’ayan Street, Modi’in 7177871, Israel

Business

Late-stage clinical-stage biopharmaceutical companies.

Introduction

BioLineRx Ltd. Incorporated in April 2003 and commenced business. The company is a biopharmaceutical company specializing in oncology and rare diseases. Its first approved product, APHEXDA, was developed and commercialized through partnerships and adopted a growth strategy of introducing licensed assets in its focus areas.

Company Financials

EPS

BLRX has released its 2024 Q3 earnings. EPS was reported at -0.02, versus the expected -0.06, beating expectations. The chart below visualizes how BLRX has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

BLRX has released its 2025 Q4 earnings report, with revenue of 194.00K, reflecting a YoY change of -98.35%, and net profit of -2.24M, showing a YoY change of 29.84%. The Sankey diagram below clearly presents BLRX's revenue sources and cost distribution.